FDA Updates Labels on 3 More Hormone Therapy Patches and Addresses Supply

What Happened

The U.S. Department of Health and Human Services announced that the FDA approved updated labeling for three additional menopausal hormone therapy (MHT) products from two applicants. All three are estradiol transdermal patches. The approved changes remove the same statements about cardiovascular disease, breast cancer and probable dementia from the boxed warning that the FDA removed from six other MHT products in February 2026.

The FDA began asking companies to submit proposed labeling revisions in November 2025, and 29 drug companies have submitted proposals so far. The agency says it is working with applicants to act on them. HHS also gave an update on efforts to expand manufacturing capacity and availability, and tied the announcement to the women’s health executive order signed on October 19 (see our coverage of the executive order).

Why It Matters

The boxed warning is the FDA’s most prominent safety label, and for more than two decades it shaped how patients and clinicians thought about hormone therapy. HHS said the label changes reflect a re-examination of the scientific literature. Fewer scary-sounding label statements may make it easier for women and clinicians to have balanced conversations about benefits and risks.

Demand is part of the story too. The FDA anticipated that updated labels would encourage more women to seek hormone therapy and says it has been working to keep up with the increase.

What This Means for Women in Perimenopause and Menopause

If you use or are considering an estradiol patch, the updated labels may change how your clinician talks about it, but the decision is still individual. Our HRT 101 guide and HRT at a Glance page walk through delivery methods, and our estradiol and progesterone dosing page explains typical dosing ranges to discuss with your prescriber.

Access and Availability

The FDA says it is in close contact with manufacturers of all approved MHT formulations and, based on current information, is not aware of an imminent nationwide shortage. It is engaging with all six manufacturers of FDA-approved estradiol patches, which have expanded production capacity, added manufacturing shifts and prioritized patch output. The agency says this has doubled overall market output over the last 12 months. It is also monitoring other forms, such as gels and creams, and has approved generic hormone therapies, including a once-weekly patch.

The FDA acknowledged that some patients have had trouble locally finding their usual product. Availability can vary by brand, strength, formulation (once-weekly versus twice-weekly) and location. Women who can’t find their patch are encouraged to speak with a pharmacist or healthcare provider about an appropriate alternative.

The FDA also noted two compounding pathways: certain 503B outsourcing facilities may compound with estradiol under an FDA interim policy, and 503A pharmacy compounding remains available with a valid prescription for an individual patient. Compounded products are not FDA-approved, so talk with your clinician about whether one is appropriate. Use our HRT price checker to compare costs, and check our FSA-eligible menopause products page to see what may qualify for FSA spending.

Benefits and Risks

Updated labeling reflects the FDA’s current reading of the evidence, but hormone therapy is still not right for everyone. The risks and benefits depend on your age, how long it has been since menopause, your personal and family history and the type of therapy. Labels continue to carry prescribing and safety information, so this is a conversation to have with your clinician, not a reason to start or stop on your own. If you’d like help finding a clinician who focuses on midlife care, see our menopause specialist directory.

Next Steps: What to Watch For

With 29 companies having submitted proposed label changes, more updates are likely. Watch for additional product approvals and for supply updates on patches, gels and creams. The FDA also said it is exploring over-the-counter access for vaginal estrogen, which we cover in our story on over-the-counter vaginal estrogen.

What This Means for Your Midlife Health

The conversation around hormone therapy has changed quickly this year, from FDA labeling to professional guidance such as the ACOG guideline update. Staying informed helps you ask better questions at your next visit. We’ll keep following this story so you’ll know when new products, labels or supply updates come out.

Frequently Asked Questions

What did the FDA change about estradiol patches?

It approved updated labeling for three estradiol transdermal patch products, removing statements about cardiovascular disease, breast cancer and probable dementia from the boxed warning.

Is there a hormone therapy patch shortage?

The FDA says it is not aware of an imminent nationwide shortage, but acknowledges that some women have had local trouble finding their usual patch, and says patch market output has doubled over the past 12 months.

What should I do if my pharmacy can’t fill my patch?

Ask your pharmacist or prescriber about an available equivalent. Availability varies by brand, strength, once-weekly versus twice-weekly formulation and location, so don’t change your dose or schedule without guidance.

Does this mean hormone therapy is safe for everyone?

No. Label changes reflect updated evidence, but whether hormone therapy is right for you depends on your health history and preferences, so discuss it with your clinician.

This article is for informational purposes only and is not medical advice. Please consult a qualified healthcare provider about your symptoms and treatment options.

References

1. HHS. (2026). Trump Administration Delivers for Women with Major Advances in Menopause Care.
2. Contemporary OB/GYN. (2026). FDA removes boxed warnings from 3 more menopausal hormone therapy products.